PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-6.63%
Negative revenue growth while ADI stands at 11.89%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-7.29%
Negative gross profit growth while ADI is at 2.05%. Joel Greenblatt would examine cost competitiveness or demand decline.
-5.86%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-6.38%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-0.12%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.26%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-1.02%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
13.02%
Dividend growth above 1.5x ADI's 1.12%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-8.03%
Negative OCF growth while ADI is at 22.87%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-10.39%
Negative FCF growth while ADI is at 27.89%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
70.78%
10Y revenue/share CAGR 1.25-1.5x ADI's 55.41%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
29.09%
5Y revenue/share CAGR at 75-90% of ADI's 35.28%. Bill Ackman would encourage strategies to match competitor’s pace.
3.75%
3Y revenue/share CAGR under 50% of ADI's 8.77%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
60.55%
10Y OCF/share CAGR at 75-90% of ADI's 73.73%. Bill Ackman would demand strategic changes to close the gap in long-term cash generation.
50.79%
5Y OCF/share CAGR is similar to ADI's 53.10%. Walter Schloss might see parallel cost profiles or expansions producing comparable cash flow.
42.19%
3Y OCF/share CAGR above 1.5x ADI's 9.01%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
177.33%
Positive 10Y CAGR while ADI is negative. John Neff might see a substantial advantage in bottom-line trajectory.
49.47%
Positive 5Y CAGR while ADI is negative. John Neff might view this as a strong mid-term relative advantage.
200.49%
Positive short-term CAGR while ADI is negative. John Neff would see a clear advantage in near-term profit trajectory.
31.01%
10Y equity/share CAGR at 50-75% of ADI's 51.08%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
26.82%
Below 50% of ADI's 78.66%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
2.97%
Below 50% of ADI's 19.93%. Michael Burry suspects a serious short-term disadvantage in building book value.
1232.73%
10Y dividend/share CAGR above 1.5x ADI's 521.86%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.
183.53%
5Y dividend/share CAGR above 1.5x ADI's 89.38%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
100.21%
3Y dividend/share CAGR above 1.5x ADI's 48.71%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
-15.64%
Firm’s AR is declining while ADI shows 0.47%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
1.88%
We show growth while ADI is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-0.99%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
0.49%
Positive BV/share change while ADI is negative. John Neff sees a clear edge over a competitor losing equity.
-0.06%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-6.33%
Our R&D shrinks while ADI invests at 10.49%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-7.34%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.